

Supplementary Material: Appendix 3 – Results: Safety

Supplementary Table S3. Adverse events (AEs) observed in <10% during imatinib therapy in patients with GIST in the adjuvant setting at 400 mg daily

Patients/AEs	Grade					
	All		≤2		>2	
	N	% ^a	N	% ^a	N	% ^a
Total patients	300	100				
Patients with AEs ^b	272	91	227	76	45	15
Anemia	28	9	27	9	1	0.3
Vomiting	27	9	27	9	0	0
Decreased appetite	22	7	22	7	0	0
Dyspepsia	22	7	22	7	0	0
Edema	19	6	19	6	0	0
Leukopenia	18	6	16	5	2	0.7
Neutropenia	18	6	14	5	4	1
Lacrimation increased	18	6	18	6	0	0
Constipation	17	6	17	6	0	0
Upper abdominal pain	15	5	14	5	1	0.3
Nasopharyngitis	15	5	15	5	0	0
Alopecia	15	5	15	5	NA	NA

^aPercentages may not add up to 100 due to rounding.

^bData were missing in 28 patients (9%).

^cAEs occurring at an incidence of <10%, sorted by decreasing incidence.

NA not applicable